Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

Summaries of opinion Remove Summaries of opinion filter Referrals Remove Referrals filter Direct healthcare professional communication Remove Direct healthcare professional communication filter European public assessment reports (EPAR) (229) Apply European public assessment reports (EPAR) filter Withdrawn applications (50) Apply Withdrawn applications filter Paediatric investigation plans (118) Apply Paediatric investigation plans filter Orphan designations (254) Apply Orphan designations filter

Product number

Opinion status

Negative (2) Apply Negative filter Positive (12) Apply Positive filter

Application type

Initial authorisation (5) Apply Initial authorisation filter Post-authorisation (9) Apply Post-authorisation filter

Date of opinion

From:

To:

Referral name

Referral status

European Commission final decision (4) Apply European Commission final decision filter Procedure started (1) Apply Procedure started filter

Referral safety status

Yes (1) Apply Yes filter

Referral type

Article 20 procedures (4) Apply Article 20 procedures filter Article 31 referrals (1) Apply Article 31 referrals filter

Referral reference number

Referral decision making model

PRAC-CAT-CHMP-EC (1) Apply PRAC-CAT-CHMP-EC filter PRAC-CHMP-EC (2) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (1) Apply Centrally and nationally authorised products (mixed) filter Centrally authorised product(s) (4) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (3) Apply Risk minimisation measures filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Decision date

From:

To:

ATC code

Medicine type

Accelerated assessment Remove Accelerated assessment filter Conditional approval Remove Conditional approval filter Exceptional circumstances Remove Exceptional circumstances filter Orphan medicine Remove Orphan medicine filter Additional monitoring (63) Apply Additional monitoring filter Biosimilar (3) Apply Biosimilar filter Generic (11) Apply Generic filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

31 results

Remove all filtersRemove all filters

Medicine type Exceptional circumstances Remove Exceptional circumstances filter Accelerated assessment Remove Accelerated assessment filter Orphan medicine Remove Orphan medicine filter Conditional approval Remove Conditional approval filter

Medicine Direct healthcare professional communication Remove Direct healthcare professional communication filter Summaries of opinion Remove Summaries of opinion filter Referrals Remove Referrals filter

Categories Human Remove Human filter

Sort by

List item

Direct healthcare professional communication (DHPC): Zolgensma (onasemnogene abeparvovec): risk for thrombotic microangiopathy

Active substance: onasemnogene abeparvovec, DHPC type: Type II variation, Last updated: 18/03/2021
List item

Direct healthcare professional communication (DHPC): Polivy (polatuzumab vedotin) 140 mg powder for concentrate for solution for injection: Important information on plastic vial flip-off cap colour

Active substance: polatuzumab vedotin, DHPC type: Quality defect, Last updated: 04/05/2020
List item

Direct healthcare professional communication (DHPC): Prevymis (letermovir) concentrate for solution for infusion - Essential to administer through sterile 0.2 micron or 0.22 micron polyethersulfone (PES) in-line filter

Active substance: Letermovir, Last updated: 11/09/2020
List item

Direct healthcare professional communication (DHPC): Ocaliva (obeticholic acid): New contraindication for the treatment of primary biliary cholangitis (PBC) in patients with decompensated liver cirrhosis or a history of prior hepatic decompensation

Active substance: Obeticholic acid, DHPC type: New contraindication, Last updated: 09/06/2022
List item

Direct healthcare professional communication (DHPC): Natpar (parathyroid hormone) 100 micrograms/dose powder and solvent for solution for injection: expected shortage from June 30th, 2022

Active substance: parathyroid hormone, DHPC type: Medicine shortage, Last updated: 29/04/2022
List item

Referral: Adakveo (new)

crizanlizumab, associated names: Adakveo, Article 20 procedures
Status: Procedure started, Last updated: 27/01/2023

31 results

Direct healthcare professional communication (DHPC): Zolgensma (onasemnogene abeparvovec): risk for thrombotic microangiopathy

Direct healthcare professional communication (DHPC): Polivy (polatuzumab vedotin) 140 mg powder for concentrate for solution for injection: Important information on plastic vial flip-off cap colour

Direct healthcare professional communication (DHPC): Prevymis (letermovir) concentrate for solution for infusion - Essential to administer through sterile 0.2 micron or 0.22 micron polyethersulfone (PES) in-line filter

Direct healthcare professional communication (DHPC): Ocaliva (obeticholic acid): New contraindication for the treatment of primary biliary cholangitis (PBC) in patients with decompensated liver cirrhosis or a history of prior hepatic decompensation

Direct healthcare professional communication (DHPC): Natpar (parathyroid hormone) 100 micrograms/dose powder and solvent for solution for injection: expected shortage from June 30th, 2022

Referral: Adakveo (new)